ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,502.09
-0.33%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. ADC Therapeutics SA (ADCT)

  7. ADC Therapeutics SA (ADCT) Noticias

ADCT ADC Therapeutics SA

3.31
-0.13 (-3.78%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ADC Therapeutics SA ADCT NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.13 -3.78% 3.31 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.41 3.302 3.57 3.43 3.44
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/5/202406:15GLOBEADC Therapeutics to Participate in the Jefferies Global..
15/5/202406:15GLOBEADC Therapeutics to Participate in the H.C. Wainwright 2nd..
14/5/202411:32EDGAR2Form 8-K - Current report
09/5/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202406:15GLOBEADC Therapeutics to Participate in 2024 RBC Capital Markets..
08/5/202415:07EDGAR2Form 8-K - Current report
07/5/202415:06EDGAR2Form 144 - Report of proposed sale of securities
07/5/202415:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/5/202406:30GLOBEADC Therapeutics Announces $105 Million Underwritten..
06/5/202405:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/5/202405:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202405:29EDGAR2Form 8-K - Current report
06/5/202405:10GLOBEADC Therapeutics Reports First Quarter 2024 Financial..
06/5/202405:00GLOBEADC Therapeutics Announces Initial Data from..
01/5/202415:05GLOBEADC Therapeutics Makes Grants to New Employees Under..
01/5/202406:00GLOBEADC Therapeutics to Host First Quarter 2024 Financial..
04/4/202406:00GLOBEADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial..
03/4/202406:00GLOBEADC Therapeutics to Host a Virtual Research Investor Event..
01/4/202415:05GLOBEADC Therapeutics Makes Grants to New Employees Under..
13/3/202406:03IHMARKETNEWSMixed Futures Amidst Quiet Economic Schedule; Oil Prices..
13/3/202406:00GLOBEADC Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202406:15GLOBEADC Therapeutics to Participate in the Guggenheim 5th Annual..
06/3/202406:00GLOBEADC Therapeutics to Host Fourth Quarter and Year-End 2023..
05/3/202416:45GLOBEADC Therapeutics Announces Abstracts Accepted for..
05/3/202408:15EDGAR2Form 8-K - Current report
29/2/202415:30EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEADC Therapeutics to Participate in the TD Cowen 44th Annual..
24/1/202407:00EDGAR2Form 8-K - Current report
19/1/202415:30EDGAR2Form 8-K - Current report
04/1/202406:15EDGAR2Form 8-K - Current report
04/1/202406:15GLOBEADC Therapeutics Regains Compliance with NYSE Continued..
04/1/202406:00EDGAR2Form 8-K - Current report
04/1/202406:00GLOBEADC Therapeutics Provides Business Updates
02/1/202419:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202419:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202418:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202418:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/12/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202315:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/12/202304:15GLOBEADC Therapeutics Announces Initial Results from..
04/12/202315:57EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/11/202301:40PRNUSSobi to present new data at ASH 2023 Annual Meeting
15/11/202302:00GLOBEMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur..
07/11/202306:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202306:15GLOBEADC Therapeutics Receives NYSE Notice of Non-Compliance With..
07/11/202306:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202306:00GLOBEADC Therapeutics Reports Third Quarter 2023 Financial..
06/11/202306:00GLOBEADC Therapeutics to Participate in the Jefferies London..

Su Consulta Reciente

NYSE
ADCT
ADC Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados